Actively Recruiting
Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants
Led by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Updated on 2025-05-31
570
Participants Needed
1
Research Sites
565 weeks
Total Duration
On this page
Sponsors
B
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Lead Sponsor
H
Hospital Clinic of Barcelona
Collaborating Sponsor
AI-Summary
What this Trial Is About
Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression. Cross-sectional and single arm study performed on a subgroup of individuals recruited in the ALFA project. Study without therapeutic interest for the research participants (440 participants of the ALFA project who have been selected for being cognitively healthy and in their vast majority are direct descendants of patients diagnosed with Alzheimer's Disease). Each study candidate will be selected from the ALFA project (STUDY 45-65 FPM/2012) according to their clinical characteristics, their compliance to selection criteria and their desire to participate in this study. After signing this study's specific informed consent form, the neuropsychological screening and the brain MRI acquisition will be performed. Once all inclusion criteria are checked, the PET scans with 18F-Flutemetamol and 18F-FDG will be performed
CONDITIONS
Official Title
Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed the study informed consent form approved by authorities
- Men and women enrolled in the ALFA project (STUDY 45-65 FPM/2012)
- Brain MRI without incidental findings that exclude participation
- Normal cognitive function: MMSE score of 26 or higher and Semantic Fluency (animals) score of 12 or higher
- Clinical Dementia Rating (CDR) score of 0
- Good knowledge of the language and ability to read and write
- Women must be post-menopausal or have a negative pregnancy test at PET scan time
You will not qualify if you...
- Cognitive impairment present
- Clinically relevant psychiatric disorders such as major depressive disorder, generalized anxiety disorder, schizophrenia, or bipolar disorder
- Visual or hearing impairments
- History of encephalitis, seizures (except childhood febrile convulsions), or stroke
- Severe multi-stroke disease or brain tumors confirmed by MRI
- Contraindications to MRI such as metal implants or severe phobia of the scan
- Participation in a clinical study with investigational drugs within 30 days or radiopharmaceutical administration within 10 radioactive half-lives before this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
BarcelonaBeta Brain Research Center
Barcelona, Catalonia, Spain, 08005
Actively Recruiting
Research Team
K
Karine Fauria, PhD
CONTACT
C
Carolina Herrero
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here